| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 03/31/2004 | EP1401999A2 B7 related protein-2 molecules and uses thereof |
| 03/31/2004 | EP1401870A2 Antibodies against tumor necrosis factor delta (april) |
| 03/31/2004 | EP1401863A1 Somatostatin-dopamine chimeric analogs |
| 03/31/2004 | EP1401862A2 Peptide compounds for counteracting reactive oxygen species and free radicals |
| 03/31/2004 | EP1401853A1 Modulators of pharmacological agents |
| 03/31/2004 | EP1401840A1 Novel 4-amino-5,6-substituted thiopheno 2,3-d]pyrimidines |
| 03/31/2004 | EP1401839A1 Antidepressant (sssri) azaheterocyclymethyl derivatives of 7,8-dihydro-3h-t,9-dioxa-1,3-diazacyclopenta a]naphthalene |
| 03/31/2004 | EP1401838A2 Novel substituted tetracyclic imidazole derivatives, processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine |
| 03/31/2004 | EP1401831A1 Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors |
| 03/31/2004 | EP1401822A1 Naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| 03/31/2004 | EP1401820A1 5-ht receptor ligands and uses thereof |
| 03/31/2004 | EP1401819A1 5-ht receptor ligands and uses thereof |
| 03/31/2004 | EP1401813A1 New indole derivatives with 5-ht6 receptor affinity |
| 03/31/2004 | EP1401812A1 4-piperazinylindole derivatives with 5-ht6 receptor affinity |
| 03/31/2004 | EP1401808A2 Gpe analogs and peptidomimetics |
| 03/31/2004 | EP1401485A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3 4-(2- 4-methane sulfonyl oxyphenyl ethoxy)phenyl] propanoic acid or 3- 4- 2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl -(s)-2-ethoxy propanoic acid and insulin |
| 03/31/2004 | EP1401476A2 Igf antagonist peptides |
| 03/31/2004 | EP1401472A2 Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| 03/31/2004 | EP1401470A2 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use |
| 03/31/2004 | EP1401469A2 Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways |
| 03/31/2004 | EP1401464A2 Dietetic preparation with hypocholesterolemic activity |
| 03/31/2004 | EP1401461A2 Selective cox-2 inhibition from edible plant extracts |
| 03/31/2004 | EP1401453A2 Protease inhibitors |
| 03/31/2004 | EP1401451A2 Quinazoline derivatives which promote the release of parathyroid hormone |
| 03/31/2004 | EP1401441A2 Allosteric adenosine receptor modulators |
| 03/31/2004 | EP1401434A1 Modulators of peroxisome proliferator activated receptors (ppar) |
| 03/31/2004 | EP1401433A2 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| 03/31/2004 | EP1401431A2 Human growth hormone antagonists |
| 03/31/2004 | EP1401410A2 Immunomodulation and effect on cell processes relating to serotonin family receptors |
| 03/31/2004 | EP1401294A1 Method for manufacturing of free-flowing powder containing water-dispersible sterols |
| 03/31/2004 | EP1401293A1 Calorically dense liquid oral supplement |
| 03/31/2004 | EP1401290A2 Composition for regulating animal growth, method of manufacture and use thereof |
| 03/31/2004 | EP1401282A1 Stem cell differentiation |
| 03/31/2004 | EP1401281A2 Toll/interleukin-1 receptor adaptor protein (tirap) |
| 03/31/2004 | EP1401269A2 Transgenic animal model of bone mass modulation |
| 03/31/2004 | EP1401259A2 Delta-4 desaturase genes and uses thereof |
| 03/31/2004 | EP1366059A4 Methods and compositions for modulating gluconeogenesis using pgc-1 |
| 03/31/2004 | EP1301501B1 Tocotrienolquinone cyclisation product with an anti-hypercholesterol effect |
| 03/31/2004 | EP1250156A4 Method for nucleic acid transfection of cells |
| 03/31/2004 | EP1232174A4 Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| 03/31/2004 | EP1210102A4 Tgf-alpha polypeptides, functional fragments and methods of use therefor |
| 03/31/2004 | EP1181294B1 Novel derivatives and analogues of galanthamin |
| 03/31/2004 | EP1037644B1 Compositions and methods for weight reduction |
| 03/31/2004 | EP0996431B1 Synergistic compositions of lycopene and vitamin e for the prevention of ldl oxidation |
| 03/31/2004 | EP0994705B1 Therapeutic and dietary compositions containing essential fatty acids and bioactive disulphides |
| 03/31/2004 | EP0877563B1 Food and vitamin preparations containing the natural isomer of reduced folates |
| 03/31/2004 | EP0871439B1 Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds |
| 03/31/2004 | EP0777484B1 Intravenous alendronate formulations |
| 03/31/2004 | CN1486368A Methods for the production of multimeric proteins, and related compositions |
| 03/31/2004 | CN1486312A Pyrazole compounds useful as protein kinase inhibitors |
| 03/31/2004 | CN1486311A Pyrazole compounds useful as protein kinase inhibitors |
| 03/31/2004 | CN1486310A Pyrazole compounds useful as protein kinase inhibitors |
| 03/31/2004 | CN1486302A Abca-1 elevating compounds against coronary artery disease or atherosclerosis |
| 03/31/2004 | CN1486301A 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| 03/31/2004 | CN1486298A Prodrugs of excitatory amino acids |
| 03/31/2004 | CN1486204A Compositions for inducing islet neogenesis, containing gastrin/CCK receptor ligands and egf receptor ligands |
| 03/31/2004 | CN1486196A Complex of modafinil and cyclodextrin |
| 03/31/2004 | CN1486192A Binding domain-immunoglobulin fusion proteins |
| 03/31/2004 | CN1486190A Compositions containing an active fraction isolated from scutellariae barbatae and methods of use |
| 03/31/2004 | CN1486189A Use of a strain of lactobacillus reducing the risk factors involved in the metabolic syndrome |
| 03/31/2004 | CN1486181A Lipid peroxide-lowering compositions |
| 03/31/2004 | CN1485089A Jelly fungi blood fat clearing capsule |
| 03/31/2004 | CN1485054A Medication for diabetes and its preparation method |
| 03/31/2004 | CN1485044A Preparation of medication and food additive from low molecular weight agar agar |
| 03/31/2004 | CN1485037A Medication comprising nicotinic acid and tatin-like medicine |
| 03/31/2004 | CN1485030A Compound iron-copper intensified nutrient agent |
| 03/31/2004 | CN1485028A Lycopene drop pill |
| 03/31/2004 | CN1143852C Ideno-, haphto- and benzocyclohepta dihydrothizole derivatives, the production thereof and their use as anorectic medicaments |
| 03/31/2004 | CN1143681C Medicinal composition for diabetes |
| 03/30/2004 | US6713650 ABCA-1 elevating compounds |
| 03/30/2004 | US6713508 Such as 7-(3-(3-trifluoromethyl-7-propyl-6-benz-(4,5)-isoxazoloxy)propoxy)-2 -ethylchromane-2-carboxylic acid which are potent agonists of peroxisome proliferator activated receptor |
| 03/30/2004 | US6713507 Ether compounds and compositions for cholesterol management and related uses |
| 03/30/2004 | US6713491 For use as medicine for antagonising the effects of excitatory amino acids upon the nmda receptor complex |
| 03/30/2004 | US6713489 Treatment of atherosclerosis, obesity, diabetes, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemia, pancreatitis, myocardial infarction, stroke, restenosis, or syndrome x |
| 03/30/2004 | US6713487 Heterocyclic amine derivatives; for treating an inflammatory or immune disease, a cardiovascular disease, or a neurodegenerative condition |
| 03/30/2004 | US6713451 Insulin-like growth factor agonist molecules |
| 03/30/2004 | US6713053 Use of IL-7 for treating auto-immune diseases and insulin-dependent diabetes mellitus in particular |
| 03/30/2004 | CA2239245C N-substituted dioxothiazolidylbenzamide derivatives and process for producing the same |
| 03/30/2004 | CA2136233C Health supplements containing phyto-oestrogens, analogues or metabolites thereof |
| 03/30/2004 | CA2133861C Preparation for the treatment of circulatory changes |
| 03/30/2004 | CA2102812C Cholesterol-lowering tocopherol analogs |
| 03/25/2004 | WO2004024943A1 Method of screening insulin content enhancer |
| 03/25/2004 | WO2004024766A1 Kdr peptides and vaccines containing the same |
| 03/25/2004 | WO2004024726A1 N-substituted-1h-indol-5-propionic acid compounds as ppar agonists useful for the treatment of diabetes |
| 03/25/2004 | WO2004024720A1 Piperazine urea derivatives as melanocortin-4 receptor agonists |
| 03/25/2004 | WO2004024705A1 Five-membered heterocyclic compounds |
| 03/25/2004 | WO2004024694A1 4-(substituted aryl)-5-hydroxyisoquinolinone derivative |
| 03/25/2004 | WO2004024679A1 Inhibitors of factor xa and other serine proteases involved in the coagulation cascade |
| 03/25/2004 | WO2004024676A1 Compounds for modulating the glycolosis enzyme complex and/or transaminase complex |
| 03/25/2004 | WO2004024673A1 Amino-propanol derivatives |
| 03/25/2004 | WO2004024184A1 Sustained release preparation |
| 03/25/2004 | WO2004024183A1 Immunization against autologous ghrelin |
| 03/25/2004 | WO2004024177A1 Method of treating or preventing obeisity and lipid metabolism disorders and compositions for use therein |
| 03/25/2004 | WO2004024167A2 Use of prebiotics, preferably glucooligosaccharide, for the prevention of the onset of type ii diabetes |
| 03/25/2004 | WO2004024162A1 2-amino-4-quinazolinones as lxr nuclear receptor binding compounds |
| 03/25/2004 | WO2004024161A1 Novel 2-amino-4-oxoquinazolones as lxr nuclear receptor binding compounds with partial agonistic properites |
| 03/25/2004 | WO2004024102A2 Cosmetic or pharmaceutical composition comprising a genus halopteris brown alga extract |
| 03/25/2004 | WO2004024094A2 Methods and compositons for the use of d-malic acid to decrease serum triglyceride, cholesterol, and lipoprotein levels |
| 03/25/2004 | WO2004023870A1 Human slt transgenic animal |
| 03/25/2004 | WO2004005237B1 Method of preparing hydroxytyrosol esters, esters thus obtained and use of same |